Researchers have identified a potential therapeutic target for head and neck squamous cell carcinoma (HNSCC) through metabolomic and transcriptomic profiling. The target, AMIGO2, is involved in modulating the tumor microenvironment. Additionally, analyses of HNSCC transcriptomes have revealed heterogeneity in certain metabolic pathways, which may be associated with distinct prognoses and therapeutic vulnerabilities.